Treatment With Anifrolumab for Discoid Lupus Erythematosus

JAMA Dermatol. 2023 Feb 1;159(2):224-226. doi: 10.1001/jamadermatol.2022.5242.

Authors

Francesca Trentin¹, Chiara Tani¹, Elena Elefante¹, Chiara Stagnaro¹, Dina Zucchi^{1

2}, Marta Mosca¹

Affiliations

¹ Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
² Department of Medical Biotechnologies, University of Siena, Siena, Italy.

PMID: 36427219
DOI: 10.1001/jamadermatol.2022.5242

No abstract available

Plain language summary

This case report describes 2 women with severe and refractory discoid lupus erythematosus that was treated with anifrolumab.

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Lupus Erythematosus, Discoid* / drug therapy
Lupus Erythematosus, Systemic*

Substances

anifrolumab
Antibodies, Monoclonal, Humanized